Overview

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

Status:
RECRUITING
Trial end date:
2029-10-01
Target enrollment:
Participant gender:
Summary
To look at the effectiveness of zanzalintinib, followed by surgery, in treating advanced thyroid cancer. The safety of this treatment will also be studied.
Phase:
PHASE2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Exelixis